Big Pharma Rushes into Next-Gen Cancer Therapies with Blockbuster Deals

　　【Pharmaceutical Network | Industry Dynamics] Recently, the global pharmaceutical industry has witnessed a wave of blockbuster deals. Leading companies such as GSK, Johnson & Johnson, and Roche have successively committed substantial capital to secure cutting-edge technological assets—including highly selective small-molecule inhibitors, antibody-conjugated protein degradation platforms, and BTK protein degraders—through acquisitions and licensing collaborations. With individual transaction values exceeding $10 billion, this concentrated investment in next-generation anticancer therapies with significant potential clearly outlines the new landscape of iterative upgrading in the global precision oncology sector, reflecting the core strategic logic of multinational pharmaceutical companies vying for technological supremacy.
 

As announced on June 9 by GlaxoSmithKline (GSK), a leading UK-based pharmaceutical company, an agreement has been reached to acquire the US biotechnology firm Nuvalent for $10.6 billion. According to available information, Nuvalent specializes in the research and development of precision targeted anticancer drugs. Its core pipeline includes two next-generation inhibitors for non-small cell lung cancer (NSCLC)—zidesamtinib and neladalkib—both currently under review by the US Food and Drug Administration (FDA), with approval decisions expected in September and November of this year, respectively. Both drugs have received Breakthrough Therapy Designation and Orphan Drug Status. This acquisition will significantly strengthen GSK’s portfolio in oncology. A GSK representative stated that these two potential blockbuster drugs are expected to contribute to revenue growth starting in 2027 and bolster core operating profits during the period from 2028 to 2030, when patents for dolutegravir expire.
 

Johnson & Johnson continues to expand its footprint in the field of KRAS-targeted anticancer drugs. Recently, the company acquired Firefly Bio and its Degradizer-Antibody Conjugate (DAC) platform for a $1 billion upfront payment. Data indicates that DACs reside at the intersection of Antibody-Drug Conjugates (ADCs) and Targeted Protein Degraders (TPDs). Similar to ADCs, DACs link a payload to a targeting antibody via a linker, enabling targeted delivery of the payload to cells expressing specific receptors. The key difference is that DACs carry catalytic protein degraders rather than cytotoxic chemotherapy agents, thereby driving protein degradation, including for so-called "undruggable" targets. Firefly’s Firelink DAC platform leverages its linker technology to reduce the amount of free payload in circulation and minimize its exposure to healthy cells. The company has previously highlighted preclinical studies in solid tumors and hematologic malignancies, where a single dose of Firefly’s DAC demonstrated "significant tumor volume reduction" at very low doses. Johnson & Johnson stated that Firefly expands its position in the "pan-KRAS" molecular space, which aims to target all variant forms of the KRAS protein.
 

Furthermore, Roche recently entered into a global collaboration agreement with Nurix Therapeutics to jointly develop and commercialize bexobrutideg (NX-5948), an oral BTK degrader under development by Nurix, for the treatment of various hematologic malignancies, multiple sclerosis, and chronic spontaneous urticaria. Under the terms of the agreement, Nurix will receive a $700 million upfront payment and is eligible to receive up to $2.3 billion in development, regulatory, and sales milestone payments.
 

Data indicate that bexobrutideg is an oral, blood-brain barrier-penetrant, highly selective BTK protein degrader. Unlike traditional BTK inhibitors that merely block kinase activity, this agent leverages the body’s own protein degradation system to eliminate intracellular BTK protein, thereby abolishing both its kinase activity and scaffolding signaling functions. Its catalytic mechanism enables a single drug molecule to degrade thousands of BTK proteins, sustaining pharmacological activity at very low drug concentrations. In early clinical studies, the drug demonstrated high overall response rates in patients with chronic lymphocytic leukemia (CLL), including those who had developed resistance to existing BTK inhibitors, as well as in patients with primary central nervous system lymphoma (PCNSL) who were refractory to conventional therapies. In addition to hematologic oncology indications, the parties plan to expand the clinical development of the drug into immunology and neurology, including conducting Phase II clinical trials for multiple sclerosis and chronic spontaneous urticaria. Currently, a Phase III clinical trial of bexobrutideg for chronic lymphocytic leukemia is underway.
 

The aforementioned three blockbuster transactions span multiple cutting-edge technological domains, including small-molecule inhibitors, antibody-conjugated protein degraders, and BTK-targeted protein degraders, further confirming that precision oncology remains a core, high-growth sector with substantial long-term potential in the pharmaceutical industry. For patients, this dual race driven by capital and technology will deliver novel anticancer drugs with superior efficacy, reduced drug resistance, and broader indications, offering new hope for survival to cancer patients.
 

Furthermore, the patent cliff has compelled leading pharmaceutical companies to accelerate the strengthening of their pipelines. By leveraging mergers and acquisitions (M&A) and business development (BD) partnerships, these companies aim to shorten internal R&D cycles, rapidly acquire high-certainty late-stage clinical assets, and offset revenue pressures caused by the expiration of patents on mature products. As some analysts have pointed out, GSK’s recent high-priced acquisition reflects the urgency with which it is addressing the pressure of the “patent cliff.” The company’s shingles vaccine, Shingrix, has shown signs of declining momentum in the U.S. market, while several of its HIV drugs are also facing the impact of patent expirations. Over the past year and a half, GSK has successively completed acquisitions of multiple biotechnology firms, including IDRx and RAPT Therapeutics, and has established collaborations with Chinese enterprises such as Hengrui Medicine and Chia Tai Tianqing.
 

Disclaimer: Under no circumstances shall the information contained herein or the opinions expressed constitute investment advice to any person.